Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Michael H. Le, Yee Hui Yeo, Biyao Zou, Scott Barnet, Linda Henry, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol. 2022;28(4):841-850.   Published online 2022 Sep 19     DOI: https://doi.org/10.3350/cmh.2022.0239
Citations to this article as recorded by Crossref logo
Evolving Global Etiology of Hepatocellular Carcinoma (HCC): Insights and Trends for 2024
Abraham Koshy
Journal of Clinical and Experimental Hepatology.2025; 15(1): 102406.     CrossRef
The liver manifestation of metabolic syndrome is now called MASLD - an up-to-date view of the most common liver disease today
Václav Šmíd, Karel Dvořák
Vnitřní lékařství.2024; 70(1): E8.     CrossRef
The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis
Ehsan Amini-Salehi, Soheil Hassanipour, Mohammad-Hossein Keivanlou, Milad Shahdkar, Mahdi Orang Goorabzarmakhi, Azin Vakilpour, Farahnaz Joukar, Mohammad Hashemi, Nazila Sattari, Mohammadreza Javid, Fariborz Mansour-Ghanaei
Nutrition Reviews.2024; 82(6): 815.     CrossRef
Stemness markers in hepatocellular carcinoma of Eastern vs. Western population: Etiology matters?
Caecilia HC Sukowati, Korri El-Khobar, Chyntia Olivia Maurine Jasirwan, Juferdy Kurniawan, Rino Alvani Gani
Annals of Hepatology.2024; 29(1): 101153.     CrossRef
Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review
Lidia Castagneto-Gissey, Stefan R. Bornstein, Geltrude Mingrone
Metabolism.2024; 151: 155721.     CrossRef
Reply
Jong Woo Hahn, Soeun Kim, Dong Keon Yon
Clinical Gastroenterology and Hepatology.2024; 22(4): 905.     CrossRef
Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting
Udita Gupta, Thomas Ruli, Danyaal Buttar, Mohamed Shoreibah, Meagan Gray
The American Journal of the Medical Sciences.2024; 367(2): 77.     CrossRef
Walking the VLDL tightrope in cardiometabolic diseases
Mindy Kim, Ze Zheng
Trends in Endocrinology & Metabolism.2024;[Epub]     CrossRef
Exclusive liquor and cocktail consumption is associated with at‐risk fibrosis among nonheavy alcohol users with metabolic dysfunction‐associated steatotic liver disease
Peng‐sheng Ting, Wei‐Ting Lin, Chiung‐Kuei Huang, Hui‐Yi Lin, Tung‐Sung Tseng, Po‐Hung Chen
Alcohol: Clinical and Experimental Research.2024; 48(1): 88.     CrossRef
Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
James A Thomas, Bradley J Kendall, Hashem B El-Serag, Aaron P Thrift, Graeme A Macdonald
The Lancet Gastroenterology & Hepatology.2024; 9(2): 159.     CrossRef
Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements
Mislav Barisic-Jaman, Marko Milosevic, Viktoria Skurla, David Dohoczky, Josip Stojic, Petra Dinjar Dinjar Kujundzic, Maja Cigrovski Cigrovski Berkovic, Ana Majic-Tengg, Ana Matijaca, Tomo Lucijanic, Mirjana Kardum-Pejic, Vlatka Pandzic Jaksic, Srecko Maru
Biomedicines.2024; 12(2): 323.     CrossRef
Molecular Insights of Nonalcoholic Fatty Liver Disease Pathogenesis
Reham Mohammed Dawood, Ghada Maher Salum, Mai Abd El-Meguid, Basma EL-sayed Fotouh
Journal of Interferon & Cytokine Research.2024; 44(3): 111.     CrossRef
Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction
Wasitha P. D. W. Thilakarathna, H. P. Vasantha Rupasinghe
Molecules.2024; 29(3): 709.     CrossRef
Suv39h1 contributes to activation of hepatic stellate cells in non-alcoholic fatty liver disease by enabling anaerobic glycolysis
Xiaoyan Wu, Yuzhou Shen, Yufei Meng, Jinsi Chen, Yongchen Zhang, Sheng Zeng, Huihui Xu
Life Sciences.2024; 341: 122498.     CrossRef
Self-management behaviours in adults with non-alcoholic fatty liver disease: a cross-sectional survey from China
Run Zhou, Binbin Zhang, Wei Zhang, Tingting Kong, Jie Fu, Jie Li, Junping Shi
BMJ Open.2024; 14(2): e078333.     CrossRef
Updated Insights into Probiotics and Hepatobiliary Diseases
Xiaoyu Xu, Cheng Zhang, Guoyi Tang, Ning Wang, Yibin Feng
Biomedicines.2024; 12(3): 515.     CrossRef
Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study
Majd B. Aboona, Claire Faulkner, Pooja Rangan, Cheng Han Ng, Daniel Q. Huang, Mark Muthiah, Moises I. Nevah Rubin, Ma Ai Thanda Han, Michael B. Fallon, Donghee Kim, Vincent L. Chen, Karn Wijarnpreecha
Liver International.2024; 44(6): 1316.     CrossRef
Optimizing surveillance of low-risk metabolic dysfunction associated steatotic liver disease using transient elastography
Harish Gopalakrishna, Gayatri B. Nair, Roham Salman Roghani, Natarajan Ravendhran, Yaron Rotman
European Journal of Gastroenterology & Hepatology.2024; 36(4): 476.     CrossRef
Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Avneet Singh, Adam Buckholz, Sonal Kumar, Carolyn Newberry
Nutrients.2024; 16(5): 658.     CrossRef
Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo
Gut and Liver.2024; 18(2): 283.     CrossRef
Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression
Ignazio S Piras, Johanna K DiStefano
Life Science Alliance.2024; 7(6): e202302517.     CrossRef
Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen
Clinical and Molecular Hepatology.2024; 30(2): 235.     CrossRef
In response to: Steatotic liver disease-know your enemies
Michael H. Le, Linda Henry, Mindie H. Nguyen
Clinical and Molecular Hepatology.2024; 30(2): 284.     CrossRef
Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta‐analysis
Fajuan Rui, Elizabeth Garcia, Xinyu Hu, Wenjing Ni, Qi Xue, Yayun Xu, Xiaoming Xu, Junping Shi, Mindie H. Nguyen, Ramsey C. Cheung, Jie Li
Journal of Viral Hepatitis.2024; 31(7): 372.     CrossRef
The impact of county-level food access on the mortality and post-transplant survival among patients with steatotic liver disease
Yutaka Endo, Diamantis I. Tsilimigras, Mujtaba Khalil, Jason Yang, Selamawit Woldesenbet, Kazunari Sasaki, Ashley Limkemann, Austin Schenk, Timothy M. Pawlik
Surgery.2024; 176(1): 196.     CrossRef
Omics-based biomarkers as useful tools in metabolic dysfunction-associated steatotic liver disease clinical practice: How far are we?
Julieta Trinks, María F Mascardi, Adrián Gadano, Sebastián Marciano
World Journal of Gastroenterology.2024; 30(14): 1982.     CrossRef
Burden of liver disease in Brazil, 1996–2022: a retrospective descriptive study of the epidemiology and impact on public healthcare
João Sérgio Fonseca Guimarães, Jordana Almeida Mesquita, Thais Yuki Kimura, Ana Luíza Matos Oliveira, M. Fatima Leite, André Gustavo Oliveira
The Lancet Regional Health - Americas.2024; 33: 100731.     CrossRef
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes
Zobair M. Younossi, Pegah Golabi, Jillian Kallman Price, Soroor Owrangi, Nagashree Gundu-Rao, Romona Satchi, James M. Paik
Clinical Gastroenterology and Hepatology.2024; 22(10): 1999.     CrossRef
Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma
Takahiro Kodama, Tetsuo Takehara
Seminars in Liver Disease.2024; 44(02): 147.     CrossRef
Association between biological aging and the risk of mortality in individuals with non-alcoholic fatty liver disease: A prospective cohort study
Haili Wang, Zhenqiu Liu, Hong Fan, Chengnan Guo, Xin Zhang, Yi Li, Xinyu Han, Tiejun Zhang
Archives of Gerontology and Geriatrics.2024; 124: 105477.     CrossRef
An Electronic Health Record Model for Predicting Risk of Hepatic Fibrosis in Primary Care Patients
Aaron P. Thrift, Theresa H. Nguyen Wenker, Kyler Godwin, Maya Balakrishnan, Hao T. Duong, Rohit Loomba, Fasiha Kanwal, Hashem B. El-Serag
Digestive Diseases and Sciences.2024; 69(7): 2430.     CrossRef
Liver disease in patients with transfusion-dependent β-thalassemia: The emerging role of metabolism dysfunction-associated steatotic liver disease
Nikolaos Fragkou, Efthimia Vlachaki, Ioannis Goulis, Emmanouil Sinakos
World Journal of Hepatology.2024; 16(5): 671.     CrossRef
Single nucleotide polymorphisms in the cannabinoid CB2 receptor: Molecular pharmacology and disease associations
Tahira Foyzun, Maddie Whiting, Kate K. Velasco, Jessie C. Jacobsen, Mark Connor, Natasha L. Grimsey
British Journal of Pharmacology.2024; 181(15): 2391.     CrossRef
Diagnostic indicators and lifestyle interventions of metabolic-associated fatty liver disease
Tianzhu Chen, Xiang Qin, Jianping Jiang, Beihui He
Frontiers in Nutrition.2024;[Epub]     CrossRef
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
Huai Zhang, Giovanni Targher, Christopher D. Byrne, Seung Up Kim, Vincent Wai-Sun Wong, Luca Valenti, Myer Glickman, Jaime Ponce, Christos S. Mantzoros, Javier Crespo, Henning Gronbaek, Wah Yang, Mohammed Eslam, Robert J. Wong, Mariana Verdelho Machado, M
Hepatology International.2024; 18(4): 1178.     CrossRef
Association between hemoglobin and non-alcoholic fatty liver disease (NAFLD) in United States adults: Results from NHANES 2017–2020
Kang Yao, Zheng Chen, Wei Zhou, Zhihua Liu, Wei Cui
Preventive Medicine Reports.2024; 44: 102798.     CrossRef
Mapping the global research landscape on nonalcoholic fatty liver disease and insulin resistance: A visualization and bibliometric study
Sa'ed H Zyoud, Omar E Hegazi, Samer O Alalalmeh, Muna Shakhshir, Faris Abushamma, Shadi Khilfeh, Samah W Al-Jabi
World Journal of Hepatology.2024; 16(6): 951.     CrossRef
Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease
Jennie Cao, Andy Shon, Luke Yoon, Aya Kamaya, Justin R. Tse
European Radiology.2024;[Epub]     CrossRef
Persons with metabolic dysfunction‐associated steatotic liver disease are at increased risk of severe depression
Hanne Åström, Ying Shang, Hannes Hagström, Axel Wester
Liver International.2024;[Epub]     CrossRef
An examination of global research trends for exploring the associations between the gut microbiota and nonalcoholic fatty liver disease through bibliometric and visualization analysis
Sa’ed H. Zyoud, Samer O. Alalalmeh, Omar E. Hegazi, Muna Shakhshir, Faris Abushamma, Samah W. Al-Jabi
Gut Pathogens.2024;[Epub]     CrossRef
Mechanism of epigallocatechin gallate in treating non-alcoholic fatty liver disease: Insights from network pharmacology and experimental validation
Danting Mao, Jianwei Guo, Kunli Yang, Fan Yang, Jiaojiao Peng, Xu Jia, Ziren Luo, Lu Liu, Enjie Yang, Rui Tang, Haitao Lan, Qian Zheng
Biochemical and Biophysical Research Communications.2024; 734: 150424.     CrossRef
Dysfunctional VLDL metabolism in MASLD
Urko M. Marigorta, Oscar Millet, Shelly C. Lu, José M. Mato
npj Metabolic Health and Disease.2024;[Epub]     CrossRef
A systematic review and meta-analysis of randomized controlled trials: effects of mediterranean diet and low-fat diet on liver enzymes and liver fat content of NAFLD
Yalan Xiong, Xinyu Shi, Xinying Xiong, Shenyu Li, Hanhua Zhao, Hualing Song, Jianying Wang, Lei Zhang, Shengfu You, Guang Ji, Baocheng Liu, Na Wu
Food & Function.2024; 15(16): 8248.     CrossRef
Food inequity and insecurity and MASLD: burden, challenges, and interventions
Shira Zelber-Sagi, Patrizia Carrieri, Juan M. Pericàs, Dana Ivancovsky-Wajcman, Zobair M. Younossi, Jeffrey V. Lazarus
Nature Reviews Gastroenterology & Hepatology.2024; 21(10): 668.     CrossRef
A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD
Nimish Thakral, Hailemichael Desalegn, Luis Antonio Diaz, Daniel Cabrera, Rohit Loomba, Marco Arrese, Juan Pablo Arab
Seminars in Liver Disease.2024;[Epub]     CrossRef
Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals
Kahei Au, Ming-Hua Zheng, Wei-Jei Lee, Omar M. Ghanem, Kamal Mahawar, Asim Shabbir, Carel W. le Roux, Giovanni Targher, Christopher D. Byrne, Yusuf Yilmaz, Luca Valenti, Giada Sebastiani, Sombat Treeprasertsuk, Hannah Xiaoyan Hui, Nasser Sakran, Manoel Ga
Current Obesity Reports.2024;[Epub]     CrossRef
Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes
Merve Cebi, Yusuf Yilmaz
Frontiers in Immunology.2024;[Epub]     CrossRef
Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease
Xianhua Mao, Xinrong Zhang, Leslie Kam, Nicholas Chien, Rongtao Lai, Ka-Shing Cheung, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H Nguyen
Gut.2024; : gutjnl-2024-332481.     CrossRef
Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches
Shifat-E Ferdous, Jessica M. Ferrell
International Journal of Molecular Sciences.2024; 25(16): 8731.     CrossRef
Novel insights into causal effects of maternal nonalcoholic fatty liver disease on adverse pregnancy outcomes: evidence from Human Genetics and Mendelian Randomization Study
Qiuyan Luo, Guoting Liu, Qiulan Li, Jinghong Lu, Wenjing Zheng, Yukui Huang, Cun Li
European Journal of Clinical Nutrition.2024;[Epub]     CrossRef
Role of Growth Hormone Therapy in Metabolic-Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
Deep Dutta, Lakshmi Nagendra, Ritin Mohindra, Saptarshi Bhattacharya, Ameya Joshi, ABM Kamrul-Hasan
Indian Journal of Endocrinology and Metabolism.2024; 28(4): 336.     CrossRef
Meta-analysis of randomized controlled trials of the effects of synbiotics, probiotics, or prebiotics in controlling glucose homeostasis in non-alcoholic fatty liver disease patients
Siqi Ding, Qing Hong, Yuanyue Yao, Minwen Gu, Jie Cui, Wenhui Li, Jian Zhang, Chengcheng Zhang, Jinchi Jiang, Yonghong Hu
Food & Function.2024;[Epub]     CrossRef
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease
Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim
Liver International.2023; 43(3): 608.     CrossRef
Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”
Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
Clinical and Molecular Hepatology.2023; 29(1): 185.     CrossRef
Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
Min-Kyu Kang, Min-Cheol Kim
Medicina.2023; 59(2): 375.     CrossRef
The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review
George Chen, Bubu Banini, Albert Do, Joseph K. Lim
Clinical and Molecular Hepatology.2023; 29(Suppl): S319.     CrossRef
Global incidence and prevalence of nonalcoholic fatty liver disease
Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah
Clinical and Molecular Hepatology.2023; 29(Suppl): S32.     CrossRef
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
Sang Bong Ahn
Clinical and Molecular Hepatology.2023; 29(Suppl): S150.     CrossRef
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Hyunwoo Oh, Won Sohn, Yong Kyun Cho
Clinical and Molecular Hepatology.2023; 29(Suppl): S261.     CrossRef
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
Yi-wen Shi, Jian-Gao Fan
Clinical and Molecular Hepatology.2023; 29(Suppl): S228.     CrossRef
Risk Stratification for Sarcopenic Obesity in Nonalcoholic Fatty Liver Disease
Rongtao Lai, Mindie H. Nguyen
Clinical Gastroenterology and Hepatology.2023; 21(11): 2984.     CrossRef
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
Young-Joo Jin
Clinical and Molecular Hepatology.2023; 29(2): 414.     CrossRef
The growing burden of non-alcoholic fatty liver disease on mortality
Ju-Yeon Cho, Won Sohn
Clinical and Molecular Hepatology.2023; 29(2): 374.     CrossRef
Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—Current Background, Hopes, and Perspectives
Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Gabriela Ștefănescu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai
Metabolites.2023; 13(5): 581.     CrossRef
The Role of Choline, Soy Isoflavones, and Probiotics as Adjuvant Treatments in the Prevention and Management of NAFLD in Postmenopausal Women
Johanna K. DiStefano
Nutrients.2023; 15(12): 2670.     CrossRef
Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease
Olufunto O. Badmus, Terry D. Hinds, David E. Stec
Current Hypertension Reports.2023; 25(8): 151.     CrossRef
Cardiovascular outcomes among persons with HIV and nonalcoholic fatty liver disease
Sepiso K. Masenga, Lweendo Muchaili, Benson M. Hamooya
AIDS.2023; 37(8): 1329.     CrossRef
Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis
Bryan Tan, Xin-Hui Pan, Han Shi Jocelyn Chew, Rachel Sze Jen Goh, Chaoxing Lin, Vickram Vijay Anand, Ethan Cheng Zhe Lee, Kai En Chan, Gwyneth Kong, Christen En Ya Ong, Hui Charlotte Chung, Dan Yock Young, Mark Y. Chan, Chin Meng Khoo, Anurag Mehta, Mark
International Journal of Obesity.2023; 47(8): 677.     CrossRef
Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models
Amina Basha, Sarah C. May, Ryan M. Anderson, Niharika Samala, Raghavendra G. Mirmira
International Journal of Molecular Sciences.2023; 24(12): 9996.     CrossRef
Transient elastography with controlled attenuation parameter versus two-dimensional shear wave elastography with attenuation imaging for the evaluation of hepatic steatosis and fibrosis in NAFLD
Jung Wook Seo, Youe Ree Kim, Jong Keon Jang, So Yeon Kim, Young Youn Cho, Eun Sun Lee, Dong Ho Lee
Ultrasonography.2023; 42(3): 421.     CrossRef
The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study
Xinyu Wang, Shuhang Wei, Yingnan Wei, Xueqi Wang, Feng Xiao, Yuemin Feng, Qiang Zhu
European Journal of Gastroenterology & Hepatology.2023; 35(8): 889.     CrossRef
Lifestyle interventions in nonalcoholic fatty liver disease
Zobair M. Younossi, Shira Zelber-Sagi, Linda Henry, Lynn H. Gerber
Nature Reviews Gastroenterology & Hepatology.2023; 20(11): 708.     CrossRef
The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B
Xianhua Mao, Lung Yi Mak, Wai-Kay Seto
Clinical and Molecular Hepatology.2023; 29(3): 690.     CrossRef
Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study
Matina Kouvari, Laura Valenzuela-Vallejo, Valentina Guatibonza-Garcia, Stergios A. Polyzos, Yixiang Deng, Michail Kokkorakis, Melih Agraz, Sophia C. Mylonakis, Angeliki Katsarou, Ornella Verrastro, Georgios Markakis, Mohammed Eslam, Georgios Papatheodorid
Metabolism.2023; 147: 155666.     CrossRef
Ca2+ signaling and the Hippo pathway: Intersections in cellular regulation
Samar Sayedyahossein, Louise Thines, David B. Sacks
Cellular Signalling.2023; 110: 110846.     CrossRef
The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study
Matina Kouvari, Sophia C. Mylonakis, Angeliki Katsarou, Laura Valenzuela-Vallejo, Valentina Guatibonza-Garcia, Michail Kokkorakis, Ornella Verrastro, Giulia Angelini, Georgios Markakis, Mohammed Eslam, Jacob George, Georgios Papatheodoridis, Geltrude Ming
Diabetes Research and Clinical Practice.2023; 203: 110870.     CrossRef
Uniting to defeat steatotic liver disease: A global mission to promote healthy livers and healthy lives
Aleksander Krag, Maria Buti, Jeffrey V. Lazarus, Alina M. Allen, Jacqueline Bowman, Patrizia Burra, Giacomo Donnini, Ajay Duseja, Manal H. El-Sayed, Amalia Gastaldelli, Ben Hainsworth, Tom H. Karlsen, Michael Kessler, Marko Korenjak, Henry E. Mark, Jake P
Journal of Hepatology.2023; 79(5): 1076.     CrossRef
Unraveling the link between insulin resistance and Non-alcoholic fatty liver disease (or metabolic dysfunction-associated steatotic liver disease): A Narrative Review
Fateme Ziamanesh, Mehdi Mohammadi, Sholeh Ebrahimpour, Ozra Tabatabaei-Malazy, Asieh Mosallanejad, Bagher Larijani
Journal of Diabetes & Metabolic Disorders.2023; 22(2): 1083.     CrossRef
A global action agenda for turning the tide on fatty liver disease
Jeffrey V. Lazarus, Henry E. Mark, Alina M. Allen, Juan Pablo Arab, Patrizia Carrieri, Mazen Noureddin, William Alazawi, Naim Alkhouri, Saleh A. Alqahtani, Quentin M. Anstee, Marco Arrese, Ramon Bataller, Thomas Berg, Paul N. Brennan, Patrizia Burra, Grac
Hepatology.2023;[Epub]     CrossRef
Global health burden of cirrhosis and other chronic liver diseases (CLDs) due to non-alcoholic fatty liver disease (NAFLD): A systematic analysis for the global burden of disease study 2019
Jie Li, Qingzhi Wang, Wenjing Ni, Chuan Liu, Zhihui Li, Xiaolong Qi
Global Transitions.2023; 5: 160.     CrossRef
The Impact of Intermittent Fasting on Non-Alcoholic Fatty Liver Disease in Older Adults: A Review of Clinicaltrials.gov Registry
Nasser Alorfi, Ahmed Ashour
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 3115.     CrossRef
Update on the Obesity Epidemic: After the Sudden Rise, Is the Upward Trajectory Beginning to Flatten?
Chrysi Koliaki, Maria Dalamaga, Stavros Liatis
Current Obesity Reports.2023; 12(4): 514.     CrossRef
Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, Sakura Iida, Hisayuki Katsuyama
International Journal of Molecular Sciences.2023; 24(20): 15473.     CrossRef
An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease
Timothy J. Kendall, Maria Jimenez-Ramos, Frances Turner, Prakash Ramachandran, Jessica Minnier, Michael D. McColgan, Masood Alam, Harriet Ellis, Donald R. Dunbar, Gabriele Kohnen, Prakash Konanahalli, Karin A. Oien, Lucia Bandiera, Filippo Menolascina, An
Nature Medicine.2023; 29(11): 2939.     CrossRef
Association of nonalcoholic fatty liver disease and growth hormone deficiency: a systematic review and meta-analysis
Tingting Kong, Yunpeng Gu, Lei Sun, Run Zhou, Jie Li, Junping Shi
Endocrine Journal.2023; 70(10): 959.     CrossRef
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study
Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem K. Oz, Ayse Erden, Emily Truong, Ju Dong Yang, Mazen Noureddin, Alina M. Allen, Rohit Loomba, Veeral Ajmera
Hepatology.2023;[Epub]     CrossRef
The Impact and Burden of Dietary Sugars on the Liver
Helaina E. Huneault, Ana Ramirez Tovar, Cristian Sanchez-Torres, Jean A. Welsh, Miriam B. Vos
Hepatology Communications.2023;[Epub]     CrossRef
Transcriptomics of MASLD Pathobiology in African American Patients in the Washington DC Area †
Tanmoy Mondal, Coleman I. Smith, Christopher A. Loffredo, Ruth Quartey, Gemeyel Moses, Charles D. Howell, Brent Korba, Bernard Kwabi-Addo, Gail Nunlee-Bland, Leanna R. Rucker, Jheannelle Johnson, Somiranjan Ghosh
International Journal of Molecular Sciences.2023; 24(23): 16654.     CrossRef
Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States
Pedro Ochoa-Allemant, Jorge A. Marrero, Marina Serper
Hepatology Communications.2023;[Epub]     CrossRef
The Influence of Coffee on Reducing Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: A Review
Manpreet Kaur, Shanmathi Murugesan, Sachpreet Singh, Katherine N Uy, Jasjeet Kaur, Navina Mann, Rajneet K Sekhon
Cureus.2023;[Epub]     CrossRef
International diet quality index and revised diet quality index relationship with non-alcoholic fatty liver disease: a case-control study
Narjes Najibi, Mitra Kazemi Jahromi, Farshad Teymoori, Hossein Farhadnejad, Ammar Salehi-Sahlabadi, Parvin Mirmiran
BMC Gastroenterology.2023;[Epub]     CrossRef
Developmental Programming: Impact of Prenatal Exposure to Bisphenol A on Senescence and Circadian Mediators in the Liver of Sheep
Giuliana Motta, Soundara Viveka Thangaraj, Vasantha Padmanabhan
Toxics.2023; 12(1): 15.     CrossRef
Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings
Chul-min Lee, Eileen L. Yoon, Mimi Kim, Bo-Kyeong Kang, Seon Cho, Eun-Hee Nah, Dae Won Jun
Hepatology.2023;[Epub]     CrossRef
Nonalcoholic fatty liver disease: a review of physiology, treatments, and market outlook
Pammar Aryan
Advances in Tissue Engineering & Regenerative Medicine: Open Access.2023; 9(1): 42.     CrossRef